(Q37111879)

18 August 2017

Escitalopram in the treatment of obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

18 August 2017

0 references

1 reference

1

Joseph Zohar

1 reference

18 August 2017

1 March 2008

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

3

1 reference

18 August 2017

339-349

1 reference

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Adults with early-onset obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Escitalopram versus citalopram: the surprising role of the R-enantiomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

The clinical pharmacokinetics of escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Prevention of relapse in generalized anxiety disorder by escitalopram treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

Escitalopram prevents relapse of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.339

21 January 2018

Identifiers

DOI

10.1586/14737175.8.3.339

1 reference

18 August 2017

1 reference

PubMed ID

18345966